Emcure Pharma Chile S.p.a. Pharmaceutical Import Profile — Chile (DGFT 2022–2026)

Name: Emcure Pharma Chile S.p.a. Pharmaceutical Import Records from India — 3 Products, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Emcure Pharma Chile S.p.a. — Pharmaceutical Importer Profile (2026) | 3 Products, $1.6M Trade | TransData Nexus

Emcure Pharma Chile S.p.a.

Pharmaceutical Importer · Chile · Advanced Diabetes Medications Focus · $1.6M Total Trade · DGFT Verified

Emcure Pharma Chile S.p.a. is a pharmaceutical importer based in Chile with a total trade value of $1.6M across 3 products in 2 therapeutic categories. Based on 61 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Emcure Pharma Chile S.p.a. sources from 1 verified Indian supplier, with Emcure Pharmaceuticals Limited accounting for 100.0% of imports.

Emcure Pharma Chile S.p.a. — Import Portfolio & Supplier Network

Emcure Pharma Chile S.p.a. import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Emcure Pharma Chile S.p.a.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emcure Pharmaceuticals Limited	$1.1M	32	100.0%

Emcure Pharma Chile S.p.a. sources from 1 verified Indian supplier across 26 distinct formulations. The sourcing is highly concentrated — Emcure Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Emcure Pharma Chile S.p.a. Import?

Formulation	Value	Ships
Pharmaceuticals products finis product vildagliptin 50 MG tablet 2x15 vildagliptin tablets 50 MG	$137.7K	3
Pharmaceutical article / ods / product / item - encifer 100 MG	$100.0K	2
Pharmaceutical article / ods / product / item finished goods- transcept 500 MG tablet 5x10 mycophenolate mofetil tablets 500MG	$100.0K	2
Pharmaceutical article / ods / product / item - encifer 100 mginj 5x5 ML amp iron sucrose injectionusp 100MG/5ML	$100.0K	2
Solivo 20 MG tablet 6x10 leflunomide tablets 20 MG b no h251063 mfg 22 04 2025 exp 31 03 2027	$97.9K	2
Pharmaceutical article / ods / product / item -encifer 100 MG	$50.0K	1
Pharmaceutical article / ods / product / item -encifer 100 mginj 5x5 ML amp iron sucrose injectionusp 100MG/5ML	$50.0K	1
Solivo 20 MG tabs 6x10leflunomide tabs20mgb#h232022h232028 to h232030h232034 to h232037 manufacturing	$50.0K	1
Pharmaceuticals products finis product vildagliptin 50 MG tablet 4x15 vildagliptin tablets 50 MG	$50.0K	1
Pharmaceuticals products finished product cadence 100 MG tablet 5x10 flecainide acetate tablets 100 MG	$50.0K	1
Pharmaceutical pro finished product milrinona 10MG 10ML injection 1x5 soluci n inyectable 10 MG 10 ML	$48.0K	1
Solivo 20 MG tablet 6x10 leflunomide tablets 20 MG b.no.h232018 to h232021 h231992h231993	$45.1K	1
Solivo 20 MG tablet 6x10 leflunomide tablets 20 MG b no h251064a mfg 23 04 2025 exp 31 03 2027	$43.5K	1
Pause 500 MG tablet 2x10 tranexamic acid tablets 500MG b no h250379b mfg 11 02 2025 exp 31 01 2028	$42.3K	1
Viropil 50/300/300MG tabs 30sdolutegravirlamivudinetenofovir diso.fumarate tabs	$31.2K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Vildagliptin	Advanced Diabetes Medications	$869.4K	31	6.6%	4
2	Leflunomide	Immunosuppressants	$626.7K	27	2.5%	5
3	Azathioprine	Immunosuppressants	$150.0K	3	0.4%	12

Emcure Pharma Chile S.p.a. imports 3 pharmaceutical products across 2 categories into Chile totaling $1.6M.

Emcure Pharma Chile S.p.a. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Emcure Pharma Chile S.p.a. is a pharmaceutical importer and distributor based in Santiago, Chile. Established as a subsidiary of Emcure Pharmaceuticals Limited, an Indian multinational pharmaceutical company headquartered in Pune, India, Emcure Pharma Chile S.p.a. serves as a key player in the Chilean pharmaceutical market. Emcure Pharmaceuticals Limited, founded in 1981, specializes in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products across multiple therapeutic areas, including gynecology, cardiology, oncology, and HIV antivirals.

In Chile, Emcure Pharma Chile S.p.a. operates as a pharmaceutical importer, focusing on sourcing finished pharmaceutical formulations from India. The company's role in the Chilean pharmaceutical distribution network involves importing and distributing a range of pharmaceutical products, primarily targeting the advanced diabetes and immunosuppressant therapeutic categories. This strategic focus aligns with Emcure Pharmaceuticals Limited's global emphasis on complex generics, biosimilars, and injectables, catering to both domestic and international markets.

2Distribution Network

Emcure Pharma Chile S.p.a. maintains its distribution operations from its headquarters in Santiago, Chile. While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Santiago suggests a centralized distribution model. This centralization likely facilitates efficient logistics and supply chain management, enabling the company to effectively serve the Chilean market. Emcure Pharma Chile S.p.a. primarily imports finished pharmaceutical formulations from Emcure Pharmaceuticals Limited in India, indicating a streamlined supply chain focused on sourcing products from a single supplier.

3Industry Role

In the Chilean pharmaceutical supply chain, Emcure Pharma Chile S.p.a. functions as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from Emcure Pharmaceuticals Limited in India, the company plays a crucial role in introducing and distributing a range of pharmaceutical products within Chile. This position enables Emcure Pharma Chile S.p.a. to address specific therapeutic needs in the Chilean market, particularly in the advanced diabetes and immunosuppressant categories. The company's operations contribute to the diversification and availability of pharmaceutical products in Chile, enhancing access to specialized treatments for patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Emcure Pharma Chile S.p.a.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Emcure Pharma Chile S.p.a. exhibits a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single supplier: Emcure Pharmaceuticals Limited in India. This exclusive sourcing strategy indicates a strong and potentially strategic partnership between the two entities. The company's total import value from India stands at $1.6 million USD, encompassing 61 shipments and 26 unique formulations. The top three imported products—Vildagliptin, Leflunomide, and Azathioprine—account for 52.8% and 47.2% of the total import value, respectively, highlighting a focused product portfolio. This concentration suggests a stable and reliable supply chain relationship, with Emcure Pharma Chile S.p.a. likely benefiting from consistent product quality and availability. However, the reliance on a single supplier also presents potential risks, such as supply disruptions or changes in pricing strategies. To mitigate these risks, Emcure Pharma Chile S.p.a. may consider diversifying its supplier base or establishing contingency plans to ensure uninterrupted product availability.

2Supply Chain Resilience

Emcure Pharma Chile S.p.a.'s supply chain resilience is closely tied to its exclusive sourcing arrangement with Emcure Pharmaceuticals Limited in India. This singular supplier relationship offers the advantage of streamlined operations and potentially favorable terms. However, the lack of backup suppliers introduces vulnerabilities, particularly in scenarios involving supply chain disruptions, regulatory changes, or geopolitical events affecting trade routes. The company's import data indicates a focus on 26 unique formulations, suggesting a diversified product range within its portfolio. To enhance supply chain resilience, Emcure Pharma Chile S.p.a. could explore establishing relationships with additional suppliers or developing strategic partnerships to ensure a more robust and adaptable supply chain framework.

Importing Pharmaceuticals into Chile — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Chile

1Regulatory Authority & Framework

In Chile, the primary regulatory authority overseeing pharmaceutical imports and marketing is the Public Health Institute of Chile (Instituto de Salud Pública de Chile, ISP). The ISP is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the Chilean market. Key legislation governing pharmaceutical imports includes the Health Code (Código Sanitario) and the Pharmaceutical Regulations (Reglamento Sanitario de los Alimentos), which outline the requirements for importing, registering, and marketing pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining a sanitary registration from the ISP, which requires submission of comprehensive documentation, including evidence of bioequivalence, Good Manufacturing Practice (GMP) certificates, and stability data. The ISP evaluates these submissions to ensure that imported generics meet the necessary standards for public health protection.

2Import Licensing & GMP

Import licensing in Chile is governed by the Public Health Institute of Chile (ISP), which mandates that all pharmaceutical products imported into the country must have a valid sanitary registration. This registration process involves submitting detailed documentation, including GMP certificates from the manufacturing facility. The ISP recognizes GMP certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). For Indian exporters, obtaining GMP certification from these recognized organizations is essential to facilitate the importation of their products into Chile. Additionally, Indian exporters must ensure compliance with Chilean regulations regarding labeling, packaging, and product information to meet the requirements set forth by the ISP.

Emcure Pharma Chile S.p.a. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Emcure Pharma Chile S.p.a. focuses on importing pharmaceutical products in the advanced diabetes and immunosuppressant therapeutic categories. This strategic focus aligns with the growing prevalence of diabetes and autoimmune diseases in Chile, creating a significant demand for specialized treatments. By sourcing products such as Vildagliptin, Leflunomide, and Azathioprine from Emcure Pharmaceuticals Limited in India, Emcure Pharma Chile S.p.a. aims to address these specific healthcare needs. The company's product strategy reflects a commitment to providing high-quality, specialized medications to the Chilean market, thereby enhancing patient outcomes and contributing to the overall healthcare landscape.

2Sourcing Profile

Emcure Pharma Chile S.p.a. employs a sourcing strategy that centers on importing finished pharmaceutical formulations from Emcure Pharmaceuticals Limited in India. This approach allows the company to leverage Emcure Pharmaceuticals Limited's extensive product portfolio and manufacturing capabilities, ensuring a consistent supply of high-quality medications. The focus on finished formulations, rather than active pharmaceutical ingredients (APIs) or bulk drugs, indicates a strategic decision to streamline operations and maintain control over product quality and regulatory compliance. By sourcing from a single supplier, Emcure Pharma Chile S.p.a. can establish a strong partnership, facilitating efficient logistics and supply chain

Frequently Asked Questions — Emcure Pharma Chile S.p.a.

What products does Emcure Pharma Chile S.p.a. import from India?

Emcure Pharma Chile S.p.a. imports 3 pharmaceutical products across 2 categories. Top imports: Vildagliptin ($869.4K), Leflunomide ($626.7K), Azathioprine ($150.0K).

Who supplies pharmaceuticals to Emcure Pharma Chile S.p.a. from India?

Emcure Pharma Chile S.p.a. sources from 1 verified Indian suppliers. The primary supplier is Emcure Pharmaceuticals Limited (100.0% of imports, $1.1M).

What is Emcure Pharma Chile S.p.a.'s total pharmaceutical import value?

Emcure Pharma Chile S.p.a.'s total pharmaceutical import value from India is $1.6M, based on 61 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Emcure Pharma Chile S.p.a. focus on?

Emcure Pharma Chile S.p.a. imports across 2 categories. The largest: Advanced Diabetes Medications (52.8%), Immunosuppressants (47.2%).

Get Full Emcure Pharma Chile S.p.a. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.